Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Collaborative Action and Research for Engagement, Persistence and Adherence in Treatment & Health

Project description

Why chronic disease care fails

Medicine only works if people actually take it. In Europe, the biggest reason for poor health is not a lack of doctors, it is that patients often do not stick to their prescriptions. From heart disease to obesity, abandoned therapies hurt the patient and drive up public health costs. The EU-funded CarePath project aims to address this problem by reshaping long-term care. Specifically, it combines existing digital and non-digital solutions into a modular system adapted to local health services in six countries, from Germany to Spain. The project is testing new tools for primary and secondary care to support sustained use of medicines, including newer weight-loss drugs and cardiovascular treatments.

Objective

CAREPATH aims to improve chronic disease management and medication persistence by transforming the care ecosystem, ensuring personalised support for better health outcomes, and reducing healthcare costs. We focus on improving medication adherence and persistence for three prevalent chronic conditions: Obesity (BMI ≥ 30 kg/m2), Type 2 Diabetes Mellitus (T2DM), and cardiovascular diseases (CVD), including chronic heart failure (CHF), across six diverse European countries: Germany, Israel, the Netherlands, Poland, Spain, and Sweden. These countries represent various EU healthcare environments and economic statuses, emphasising the need for tailored approaches to patient care.

Our strategy involves integrating localised non-digital and digital health solutions to address the unique healthcare delivery challenges in each region. The CAREPATH toolbox collects, combines, and customises existing solutions into adaptable modules for broad application in both primary and secondary care settings. This toolbox will be tested in four studies across two settings in all six countries in both primary and secondary care. Three pilot studies in different regions as well as a proof-of-concept study in Germany will be conducted. This comprehensive evaluation, including HTA, aims to assess the toolbox's implementation and effectiveness, with a strong focus on learning what works for what groups of patients in which setting.

Recognizing the significant impact of obesity, particular emphasis is placed on treatment adherence and persistence of medications that facilitate weight loss, such as dual GIP/GLP-1 receptor agonists, but CAREPATH studies also include patients using lipid-lowering drugs, insulin, and SGLT2 inhibitors. Our goal is to empower patients by improving communication and data sharing among patients, healthcare providers, and other stakeholders, thereby supporting the entire ecosystem and alleviating the burden on healthcare systems.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-JU-IHI-2024-06-two-stage

See all projects funded under this call

Coordinator

RISE RESEARCH INSTITUTES OF SWEDEN AB
Net EU contribution
€ 700 661,25
Address
BRINELLGATAN 4
501 15 Boras
Sweden
Region
Södra Sverige Västsverige Västra Götalands län
Activity type
Research Organisations
Links
Total cost
€ 700 661,25

Participants (36)

Partners (9)